A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group

Inclusion criteria

• ✓. Patients who plan to undergo ESD for the treatment of superficial esophageal cancer
• ✓. Patients aged \>=20 years at the time of consent
• ✓. Patients with no clinical metastasis (cN0M0) by cervical to abdominal CT
• ✓. Patients with an endoscopically diagnosed depth of wall invasion remaining in the epithelium (EP) or lamina propria mucosae (LPM)
• ✓. Patients with a tumor diagnosed as \>=50% and \<100% of circumference, and with prediction that resection circumference will be \>=75% and \<100%.
• ✓. Patients with a tumor the major axis is \<=50 mm, and with prediction that a major axis of a resection will be \<=80 mm.
• ✓. If the patient has multiple lesions, the circumference of all minor lesions other than the one lesion with the largest circumference (major lesion) must be \<50%. However, if it is predicted that the major axis of the mucosal defect is \>80 mm due to treating the major and minor lesions and assembling ulcers after the treating, the patient is excluded.
• ✓. Patients with squamous cell carcinoma (including high-grade intraepithelial neoplasia) as confirmed by biopsy

Exclusion criteria